Skip to main content
. 2017 Jul 14;12(7):e0179549. doi: 10.1371/journal.pone.0179549

Table 4. Oligonucleotide primers of qRT-PCR for validation of DEGs.

Gene name Putative function GO category Pathway name Primer name Nucleotide sequence (5′-3′) Expected product
ACTIN - - - ACTIN-F TGTGTAGCGGTGAAATGCG 140bp
ACTIN-R CATCGTTTACGGCGTGGAC
METL Aspartokinase II Aspartate family amino acid biosynthetic process (Biological process) Metabolic pathways METL-F AAGGTGTAGTTGCTGGAGAGGT 130bp
METL-R GCGTGTGAAGAGACATCAAGGA
METE 5-methyltetrahydropteroyltriglutamate Methylation (Biological process) Metabolic pathways METE-F CTTACGAGGCGGGCATTCAG 151bp
METE-R AAGCGGGTGATGGCAAAGC
air-2 alanine racemase regulation of cell shape, peptidoglycan biosynthetic process (Biological process) Metabolic pathways air-2-F AACGCTTTCTCTGGCTCCCTA 125bp
air-2-R CGACATCAGCACGGCATTCA
air alanine racemase peptidoglycan biosynthetic process, alanine metabolic process (Biological process) Metabolic pathways air-F ACCGCACCTTCACCCTCAA 209bp
air-R GAACAGCACCACCTCGTCAC
AHA2142 Acetyl-CoA acetyltransferase signal transduction, metabolic process, cholesterol metabolic process (Biological process) Metabolic pathways AHA2142-F GGAGACATTGCCGAAGTGACC 118bp
AHA2142-R CTACCTCATAGTGCCGCTCAAC
gyrB1 DNA gyrase subunit B DNA topoisomerase type II (ATP-hydrolyzing) activity, ATP binding, metal ion binding, DNA replication origin binding, GTPase activity (Molecular process) Metabolic pathways gyrB1-F GCGGAATGTTGTTGGTGAAGC 173bp
gyrB1-R CTACGAAGGCGGCATCAAGG
gyrA DNA gyrase subunit A DNA topoisomerase type II (ATP-hydrolyzing) activity, magnesium ion binding, protein heterodimerization activity (Molecular process) Metabolic pathways gyrA-F GTCTTCTCGTCCACCTCCACT 222bp
gyrA-R CAACATTCCGCCTCACAACCT

The data revealed that the upregulation or downregulation of these six genes was consistent with the RNA-Seq results. Together, these results indicate that the qRT-PCR and RNA-Seq results were reliable overall; however, further studies to determine the molecular mechanisms of resistance to enrofloxacin are required (Fig 7).